glp 1 ra drugs Mapping the effectiveness and risks of GLP-1 receptor agonists List of approved and pending
Description
Overall, the results of the PIONEER-3 study together with other recent studies suggest that the introduction of semaglutide , the first oral compound of GLP-1RA in which the subcutaneous agent has shown a positive cardiovascular benefit, is an important addition to the growing list of pharmacological options for the treatment of type-2 diabetes
This is because undetectable in a small study is not the same as a guarantee of safety for everyone
Daily pill versions, pending FDA approval, are anticipated to start at $150 for initial doses
2019 Aug 21;68:211222
